BioDelivery Sciences International (BSDI) announced that it engaged in a positive meeting with the US Food and Drug Administration (FDA) regarding the clinical development program for Clonidine topical gel that will allow the program to ...
BioDelivery Sciences International and Arcion Therapeutics have signed a worldwide licensing deal for the development and commercialization of topical clonidine gel (previously ARC4558) to treat painful diabetic neuropathy (PDN) and other ...
Tags: BioDelivery, Arcion Therapeutics, topical clonidine gel development
American pharmaceutical company BioDelivery Sciences (BDSI) has completed the safety and tolerability trial of BEMA Buprenorphine/Naloxone (BNX), which is indicated for the treatment of opioid dependent patients. BDSI claims that BNX, ...
Tags: BioDelivery Sciences, BEMA Buprenorphine, opioid dependent patients
BioDelivery Sciences International, a developer of drug delivery technologies, and Endo Health Solutions have started enrolling patients for its Phase 3 clinical program of BEMA Buprenorphine, designed as a treatment for moderate to severe ...
Tags: BioDelivery Sciences International, Endo Health Solutions
BioDelivery Sciences International (BDSI) has announced the introduction of Breakyl (fentanyl buccal film) in the European Union (EU) by Meda, its commercial partner for the product in the region. The launch triggered a $2.5m final EU ...
BioDelivery Sciences International (BDSI) announced that the USPTO has granted BDSI's patent which extends the patent protection for BioErodible MucoAdhesive (BEMA) products, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone, by seven ...